Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
MANAMA, Kingdom of Bahrain, Feb. 16, 2025 (GLOBE NEWSWIRE) -- The Bahrain…
Bio X Cell Expands Global Reach with New Distribution Center in Beijing, China
LEBANON, N.H., Feb. 11, 2025 /PRNewswire/ -- Bio X Cell, the world's…
MaxCyte Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
January 30, 2025 02:00 ET | Source: MaxCyte, Inc ROCKVILLE, Md., Jan.…
TVCMALL: Leading Cell Phone Accessories Wholesaler Boosts Your Online Sales at CES 2025
Las Vegas, NV, Jan. 10, 2025 (GLOBE NEWSWIRE) -- CES 2025, one…
Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology
CHICAGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Stem Health Plus, a leader…
Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology
CHICAGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Stem Health Plus, a leader…
Mesoblasts RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
December 18, 2024 19:08 ET | Source: Mesoblast Limited RYONCIL (remestemcel-L) is…
Tessera Therapeutics Highlights Advances Across In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting
December 09, 2024 12:05 ET | Source: Tessera Therapeutics In vivo proof-of-concept…
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT…
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies
Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially…